Rheumatoid Arthritis
Conditions
Brief summary
This open-label, single-arm study will evaluate the efficacy, safety and tolerability of subcutaneously administered tocilizumab in monotherapy and/or in combination with methotrexate and other non-biologic disease modifying anti-rheumatic drug (DMARDs) in participants with active rheumatoid arthritis (RA) who are naïve to tocilizumab. Participants will receive tocilizumab 162 milligram (mg) subcutaneously weekly for 24 weeks. Participants who complete the core study achieving at least a moderate European League Against Rheumatism (EULAR) response at Week 24 may enter the extension phase and receive for a further 28 weeks at the most.
Interventions
DRUGtocilizumab
Fixed dose of 162 mg subcutaneously weekly
Sponsors
Hoffmann-La Roche
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult participants, \>/= 18 years of age * Active moderate to severe rheumatoid arthritis according to the revised (1987) American College of Rheumatology (ACR) criteria or EULAR/ACR (2010) criteria * Inadequate response or intolerant to previous therapy with two or more non-biologic disease-modifying anti-rheumatic drugs (DMARDs), one of which is methotrexate, administered in an optimal way during at least 3 months; eligible participants may also be inadequate responders to a maximum of one biologic DMARD * Oral corticosteroids (\</= 10 milligram per day (mg/day) prednisolone or equivalent) and non-steroidal anti-inflammatory drugs (NSAIDs; up to the recommended dose) are permitted if on stable dose regimen for \>/= 4 weeks prior to baseline * Permitted DMARDs are allowed if at stable dose for at least 4 weeks prior to baseline * Receiving treatment on an outpatient basis, not including tocilizumab * Females of childbearing potential and males with female partners of childbearing potential must agree to use reliable means of contraception as defined by protocol
Exclusion criteria
* Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following baseline or during long term extension (LTE) period * Rheumatic autoimmune disease other than rheumatoid arthritis * Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis * Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16 * Prior history of or current inflammatory joint disease other than RA * Exposure to tocilizumab (intravenous or subcutaneous) at any time prior to baseline * Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of screening * Intraarticular or parenteral corticosteroids within 4 weeks prior to baseline * History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies * Evidence of serious concomitant disease or disorder * Known active current or history of recurrent infection * Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks of screening * Active Tuberculosis (TB) requiring treatment within the previous 3 years * Positive for hepatitis B or hepatitis C * Primary or secondary immunodeficiency (history of or currently active) * Pregnant or lactating women * Neuropathies or other conditions that might interfere with pain evaluation * Inadequate hematologic, renal or liver function
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Full Analysis Set (FAS) | From baseline to Week 24 | The DAS28 score is a measure of the participant's disease activity calculated using the tender joint count of 28 joints (TJC28), swollen joint count of 28 joints (SJC28), patient's global assessment of disease activity visual analog scale (PGA VAS) with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. A negative change from baseline indicates an improvement. |
| Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Per Protocol Set (PPS) | From baseline to Week 24 | The DAS28 score is a measure of the participant's disease activity calculated using the TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS and acute phase reactant (ESR or CRP) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. A negative change from baseline indicates an improvement. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Simplified Disease Activity Index (SDAI)/Clinical Disease Activity Index (CDAI) | From Baseline to Week 2, Week 24 and Week 52 | SDAI is a similar index to DAS28 but has the advantage of not needing a complicated mathematical formula for its determination, but a simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS, and CRP concentration in mg/L. CDAI does not incorporate an acute response, therefore it can be used to evaluate disease activity in the absence of laboratory testing of CRP and ESR. VAS range for all assessments was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. SDAI scores ranged from 0 to 86, CDAI from 0 to 76 with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement. |
| Change in Total Tender/Swollen Joint Counts (TJC/SJC) | From Baseline to Week 2, Week 24 and Week 52 | An assessment of 66 joints for swelling and 68 joints for tenderness was made. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints were not taken into consideration for swelling or tenderness. A negative change from baseline indicates an improvement. |
| Percentage of Participants With Corticosteroid Dose Reduction/Discontinuation | Up to Week 52 | — |
| Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity | Baseline to Week 2, Week 24 and Week 52 | CDAI is calculated by simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS. VAS range was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Total CDAI score ranges from 0 to 76 with higher scores indicating increased disease activity. Clinical remission = score ≤ 2.8; Low disease activity = score \> 2.8 and ≤ 10.0; Moderate disease activity = score \> 10.0 and ≤ 22.0; High disease activity = score \> 22.0. |
| Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity | From Baseline to Week 2, Week 24 and Week 52 | SDAI is calculated by simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS, and CRP concentration in mg/L. VAS range was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Total SDAI score ranges from 0 to 86 with higher scores indicating increased disease activity. Clinical remission = score ≤ 3.3; Low disease activity = score \> 3.3 and ≤ 11.0; Moderate disease activity = score \> 11.0 and ≤ 26.0; high disease activity = score \> 26.0. |
| Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity | From Baseline to Week 2, Week 24 and Week 52 | The DAS28 score is a measure of the participant's disease activity calculated using TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. Clinical remission = score \<2.6; Low disease activity = score ≥2.6 and ≤3.2; Moderate disease activity = score \> 3.2 and ≤5.1; High disease activity = score \>5.1. |
| Percentage of Participants Achieving a Clinically Significant Improvement in DAS28 | From Baseline to Week 2, Week 24 and Week 52 | The DAS28 score is a measure of the participant's disease activity calculated using TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. DAS28 Clinically Significant Improvement was defined as a DAS28 score reduction of at least 1.2 units from Baseline. |
| Change From Baseline in Physician's Global Assessment of Disease Activity VAS | From Baseline to Week 2, Week 24 and Week 52 | Physician's Global Assessment of disease activity VAS represents the physician's assessment of the participant's current disease activity on a 100 mm horizontal VAS. The extreme left end of the line represents 0= no disease activity (symptom-free and no arthritis symptoms) and the extreme right end 100= maximum disease activity. This was completed by the Treating Physician (or designee). A negative change from baseline indicates an improvement. |
| Change From Baseline in Patient's Global Assessment of Disease Activity VAS | From Baseline to Week 2, Week 24 and Week 52 | PGA VAS represents the participant's overall assessment of their current disease activity on a 100 mm horizontal VAS. The extreme left end of the line represents 0= no disease activity (symptom-free and no arthritis symptoms) and the extreme right end 100=maximum disease activity (maximum arthritis disease activity). A negative change from baseline indicates an improvement. |
| Change From Baseline in Patient's Assessment of Pain VAS | From Baseline to Week 2 and Week 24 | Patient's Assessment of Pain VAS represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS. The extreme left end of the line represents 0=no pain and the extreme right end 100=unbearable pain. A negative change from baseline indicates an improvement. |
| Acute Phase Reactants: Change From Baseline in CRP | From Baseline to Week 2, Week 24 and Week 52 | A negative change from baseline in CRP level indicates an improvement. |
| Percentage of Participants With Positive American College of Rheumatology (ACR) Response Scores | From Baseline to Week 2, Week 24, and Week 52 | The ACR core set of outcome measures and their definition of improvement includes a \>= 20% improvement (ACR20) compared to Baseline in both SJC and TJC as well as in three out of five additional parameters: Physician's Global Assessment of disease activity VAS, PGA VAS, patient's assessment of pain VAS, Health Assessment Questionnaire-Disability Index (HAQ-DI), and acute phase reactant (CRP or ESR). VAS range for all assessments was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Achievement of an ACR50 requires a \>= 50% improvement in the same parameters and an ACR70 requires a \>= 70% improvement. |
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) | From Baseline to Week 2, Week 24 and Week 52 | The Stanford HAQ-DI is a patient-oriented outcome assessment questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities. Each category contains multiple questions, which were answered using a 4-point scale from 0 to 3. The overall index score was an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. A negative change from baseline indicates an improvement. |
| Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) | From Baseline to Week 2, Week 24 and Week 52 | The symptom-specific measure FACIT-F was developed to assess chronic illness therapy with special emphasis on fatigue in the past 7 days. In this study, only the FACIT-F short questionnaire, which is a shorter version of the initial FACIT-F questionnaire, was used. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions. The 13 items included in the FACIT-F short can be used to calculate the brief score for FACIT-F scale (score range: 0-52). A positive change from baseline indicates an improvement. |
| Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) | From Baseline to Week 4, Week 24 and Week 52 | The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over 1-month time interval. Nineteen individual items generate seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The participant self-rates each of these seven areas of sleep. Scoring of answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. Global scores range from 0 to 21 and a global sum of 5 or greater indicates a poor sleeper. Although there are several questions that request the evaluation of the participant's bed mate or roommate, these are not scored. A negative change from baseline indicates an improvement. |
| Change From Baseline in Patient Quality of Sleep VAS | From Baseline to Week 2, Week 24 and Week 52 | The Patient Quality of Sleep VAS assessment represents the participant's assessment of his/her current quality of sleep on a 100 mm horizontal VAS. The extreme left end of the line represents 0=no difficulty to sleep and the extreme right end 100=extreme sleeping difficulties. A negative change from baseline indicates an improvement. |
| Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | From Baseline to Week 4, Week 24 and Week 52 | The AIMS-SF is a reduced version of the validated AIMS2 questionnaire. The Short Form has been developed using a comprehensive expert-based approach and supported by psychometric testing. The AIMS-SF is a self-administered questionnaire to measure changes in global health, pain, mobility and social function in adult patients with arthritis and reports scores for physical, symptoms, affect, social and work assessments. Scores range from 0 to 10, higher scores indicating higher impact of arthritis on the assessments. A negative change from baseline indicates an improvement. |
| Change From Baseline in Patient Fatigue VAS | From Baseline to Week 2, Week 24 and Week 52 | The Patient Fatigue VAS assessment represents the participant's assessment of his/her current level of fatigue on a 100 mm horizontal VAS. The extreme left end of the line represents 0=no fatigue and the extreme right end 100=extreme fatigue. A negative change from baseline indicates an improvement. |
| Change From Baseline in Patient Satisfaction VAS | From Baseline to Week 2, Week 24 and Week 52 | The Patient Satisfaction VAS assessment represents the participant's assessment of his/her current satisfaction with treatment on a 100 mm horizontal VAS. The extreme left end of the line represents 0=no satisfaction and the extreme right end 100=extremely satisfied. A positive change from baseline indicates an improvement. |
| Change From Baseline in Work Instability Scale for Rheumatoid Arthritis (RA-WIS) | From Baseline to Week 24 | The 23-item RA-WIS is a simple, validated screening tool for work instability, i.e., the consequences of a mismatch between an individual's functional ability and their work tasks. This self-administered questionnaire covers a broad range of specific work-related issues and enables monitoring the risk of work disability in rheumatoid arthritis patients. The RA-WIS is scored by summing responses from all 23 scale items. The scale ranges from 0 to 23. Cut points have been established to differentiate levels of work instability: low \< 10, moderate 10-17 and high \> 17. A negative change from baseline indicates an improvement. |
| Treatment Satisfaction Questionnaire for Medication (TSQM ) Scores | Week 24 | The abbreviated 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) derived from the TSQM Version 1.4 but without the five items of the side effects domain, is a reliable and valid measure to assess participants' satisfaction with treatment. The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain. Domains included are effectiveness, convenience and global satisfaction. |
| Safety: Percentage of Participants With Adverse Events | Up to 52 weeks | An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. |
| Safety: Percentage of Participants With Anti-tocilizumab Antibodies | Baseline, Week 24 | — |
| Acute Phase Reactants: Change From Baseline in ESR | From Baseline to Week 2, Week 24 and Week 52 | A negative change from baseline in ESR indicates an improvement. |
| Percentage of Participants With Responses According to European League Against Rheumatism (EULAR ) Criteria | From Baseline to Week 2, Week 24 | EULAR response was calculated as the difference between DAS28-ESR scores at baseline and Week 24, and reported as the percentage of participants with good, moderate, or no response. Good responders = decrease from baseline \>1.2 with a DAS28 score of \<=3.2; moderate responders = decrease from baseline \>1.2 with a DAS28 score of \>3.2, or decrease from baseline \>0.6 to \<=1.2 with a DAS28 score of \<=5.1; non-responders = decrease from baseline \<=0.6 or decrease from baseline \>0.6 and \<=1.2 with a DAS28 score of \>5.1. |
Countries
Belgium, Luxembourg
Participant flow
Pre-assignment details
A total of 62 participants were screened, 57 participants were enrolled. Participants who completed the 24 Week Treatment Period achieving at least a moderate European League Against Rheumatism (EULAR) response at Week 24 were allowed to enter the Long Term Extension (LTE) Period.
Participants by arm
| Arm | Count |
|---|---|
| Tocilizumab Adults with rheumatoid arthritis received a fixed dose of tocilizumab during the 24-week open-label core study and those entering the LTE period further received a fixed dose up to a maximum of 28 weeks or until tocilizumab was commercially available and/or reimbursed whichever came first. A fixed dose of 162 mg tocilizumab was administered subcutaneously once weekly. | 57 |
| Total | 57 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| 24 Week Treatment Period | Adverse Event | 6 |
| 24 Week Treatment Period | Hypersensitivity Reaction | 1 |
| 24 Week Treatment Period | Insufficient Therapeutic Response | 1 |
| 24 Week Treatment Period | Participant Decision to Withdraw | 2 |
| 24 Week Treatment Period | Protocol Violation | 1 |
| Long Term Extension (LTE) Period | Adverse Event | 1 |
| Long Term Extension (LTE) Period | Insufficient Therapeutic Response | 1 |
Baseline characteristics
| Characteristic | Tocilizumab |
|---|---|
| Age, Continuous | 54.49 years STANDARD_DEVIATION 11.08 |
| Sex: Female, Male Female | 44 Participants |
| Sex: Female, Male Male | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 36 / 57 |
| serious Total, serious adverse events | 5 / 57 |
Outcome results
Primary
Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Full Analysis Set (FAS)
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint count of 28 joints (TJC28), swollen joint count of 28 joints (SJC28), patient's global assessment of disease activity visual analog scale (PGA VAS) with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. A negative change from baseline indicates an improvement.
Time frame: From baseline to Week 24
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tocilizumab | Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Full Analysis Set (FAS) | Baseline (n=56) | 5.55 Units on a scale | Standard Deviation 1.17 |
| Tocilizumab | Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Full Analysis Set (FAS) | Change at Week 24 (n=42) | -3.24 Units on a scale | Standard Deviation 1.47 |
Primary
Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Per Protocol Set (PPS)
The DAS28 score is a measure of the participant's disease activity calculated using the TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS and acute phase reactant (ESR or CRP) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. A negative change from baseline indicates an improvement.
Time frame: From baseline to Week 24
Population: The PPS consisted of all participants of the FAS having a value at baseline and at Week 24 for the endpoint DAS28-ESR, excluding sponsor defined deviation(s) which could have affected the evaluation of the primary endpoint (DAS28-ESR). Here, n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tocilizumab | Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Per Protocol Set (PPS) | Baseline (n= 27) | 5.73 Units on a scale | Standard Deviation 1.33 |
| Tocilizumab | Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Per Protocol Set (PPS) | Change at Week 24 (n= 20) | -3.21 Units on a scale | Standard Deviation 1.42 |
Secondary
Acute Phase Reactants: Change From Baseline in CRP
A negative change from baseline in CRP level indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tocilizumab | Acute Phase Reactants: Change From Baseline in CRP | Baseline (n=55) | 13.79 milligrams per liter (mg/L) | Standard Deviation 20.78 |
| Tocilizumab | Acute Phase Reactants: Change From Baseline in CRP | Change at Week 2 (n=54) | -13.19 milligrams per liter (mg/L) | Standard Deviation 20.64 |
| Tocilizumab | Acute Phase Reactants: Change From Baseline in CRP | Change at Week 24 (n=42) | -10.12 milligrams per liter (mg/L) | Standard Deviation 14.5 |
| Tocilizumab | Acute Phase Reactants: Change From Baseline in CRP | Change at Week 52 (n=8) | -25.07 milligrams per liter (mg/L) | Standard Deviation 23.03 |
Secondary
Acute Phase Reactants: Change From Baseline in ESR
A negative change from baseline in ESR indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tocilizumab | Acute Phase Reactants: Change From Baseline in ESR | Baseline (n=56) | 33.75 millimeters per hour (mm/hr) | Standard Deviation 28.9 |
| Tocilizumab | Acute Phase Reactants: Change From Baseline in ESR | Change at Week 2 (n=55) | -19.95 millimeters per hour (mm/hr) | Standard Deviation 18.22 |
| Tocilizumab | Acute Phase Reactants: Change From Baseline in ESR | Change at Week 24 (n=44) | -22.80 millimeters per hour (mm/hr) | Standard Deviation 24.88 |
| Tocilizumab | Acute Phase Reactants: Change From Baseline in ESR | Change at Week 52 (n=9) | -27.78 millimeters per hour (mm/hr) | Standard Deviation 23.82 |
Secondary
Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF)
The AIMS-SF is a reduced version of the validated AIMS2 questionnaire. The Short Form has been developed using a comprehensive expert-based approach and supported by psychometric testing. The AIMS-SF is a self-administered questionnaire to measure changes in global health, pain, mobility and social function in adult patients with arthritis and reports scores for physical, symptoms, affect, social and work assessments. Scores range from 0 to 10, higher scores indicating higher impact of arthritis on the assessments. A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 4, Week 24 and Week 52
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here, n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Baseline: Physical (n= 49) | 3.57 Units on a scale | Standard Deviation 1.92 |
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Change at Week 4: Physical (n= 47) | -0.57 Units on a scale | Standard Deviation 1.36 |
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Change at Week 24: Physical (n=38) | -1.41 Units on a scale | Standard Deviation 1.83 |
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Change at Week 52: Physical (n=3) | -3.62 Units on a scale | Standard Deviation 2.23 |
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Baseline: Symptom (50) | 6.33 Units on a scale | Standard Deviation 2.59 |
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Change at Week 4: Symptom (n= 48) | -1.15 Units on a scale | Standard Deviation 2.46 |
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Change at Week 24: Symptom (n=40) | -2.69 Units on a scale | Standard Deviation 2.8 |
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Change at Week 52: Symptom (n=3) | -3.89 Units on a scale | Standard Deviation 5.91 |
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Baseline: Affect (n=50) | 5.07 Units on a scale | Standard Deviation 2.22 |
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Change at Week 4: Affect (n= 48) | -0.66 Units on a scale | Standard Deviation 1.56 |
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Change at Week 24: Affect (n=40) | -1.74 Units on a scale | Standard Deviation 2.22 |
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Change at Week 52: Affect (n=3) | -4.50 Units on a scale | Standard Deviation 2.22 |
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Baseline: Social (n=50) | 5.36 Units on a scale | Standard Deviation 1.73 |
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Change at Week 4: Social (n= 48) | 0.18 Units on a scale | Standard Deviation 1.41 |
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Change at Week 24: Social (n=40) | -0.56 Units on a scale | Standard Deviation 1.61 |
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Change at Week 52: Social (n=3) | -1.46 Units on a scale | Standard Deviation 2.37 |
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Baseline: Work (n=26) | 3.17 Units on a scale | Standard Deviation 2.46 |
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Change at Week 4: Work (n= 23) | -0.92 Units on a scale | Standard Deviation 2.53 |
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Change at Week 24: Work (n=21) | -0.65 Units on a scale | Standard Deviation 2.87 |
| Tocilizumab | Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF) | Change at Week 52: Work (n=1) | 3.75 Units on a scale | — |
Secondary
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)
The symptom-specific measure FACIT-F was developed to assess chronic illness therapy with special emphasis on fatigue in the past 7 days. In this study, only the FACIT-F short questionnaire, which is a shorter version of the initial FACIT-F questionnaire, was used. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions. The 13 items included in the FACIT-F short can be used to calculate the brief score for FACIT-F scale (score range: 0-52). A positive change from baseline indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tocilizumab | Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) | Baseline (n=57) | 26.09 Units on a scale | Standard Deviation 10.75 |
| Tocilizumab | Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) | Change at Week 2 (n=57) | 2.32 Units on a scale | Standard Deviation 9.58 |
| Tocilizumab | Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) | Change at Week 24 (n=45) | 10.53 Units on a scale | Standard Deviation 12.06 |
| Tocilizumab | Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) | Change at Week 52 (n=9) | 20.89 Units on a scale | Standard Deviation 12.35 |
Secondary
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)
The Stanford HAQ-DI is a patient-oriented outcome assessment questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities. Each category contains multiple questions, which were answered using a 4-point scale from 0 to 3. The overall index score was an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tocilizumab | Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) | Baseline (n=57) | 1.44 Units on a scale | Standard Deviation 0.68 |
| Tocilizumab | Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) | Change at Week 2 (n=57) | -0.08 Units on a scale | Standard Deviation 0.43 |
| Tocilizumab | Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) | Change at Week 24 (n=46) | -0.54 Units on a scale | Standard Deviation 0.68 |
| Tocilizumab | Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) | Change at Week 52 (n=9) | -1.33 Units on a scale | Standard Deviation 0.68 |
Secondary
Change From Baseline in Patient Fatigue VAS
The Patient Fatigue VAS assessment represents the participant's assessment of his/her current level of fatigue on a 100 mm horizontal VAS. The extreme left end of the line represents 0=no fatigue and the extreme right end 100=extreme fatigue. A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tocilizumab | Change From Baseline in Patient Fatigue VAS | Baseline (n=57) | 60.19 Units on a scale | Standard Deviation 24.79 |
| Tocilizumab | Change From Baseline in Patient Fatigue VAS | Change at Week 2 (n=57) | -3.74 Units on a scale | Standard Deviation 20.68 |
| Tocilizumab | Change From Baseline in Patient Fatigue VAS | Change at Week 24 (n=46) | -21.48 Units on a scale | Standard Deviation 28.07 |
| Tocilizumab | Change From Baseline in Patient Fatigue VAS | Change at Week 52 (n=9) | -50.89 Units on a scale | Standard Deviation 26.11 |
Secondary
Change From Baseline in Patient Quality of Sleep VAS
The Patient Quality of Sleep VAS assessment represents the participant's assessment of his/her current quality of sleep on a 100 mm horizontal VAS. The extreme left end of the line represents 0=no difficulty to sleep and the extreme right end 100=extreme sleeping difficulties. A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tocilizumab | Change From Baseline in Patient Quality of Sleep VAS | Baseline (n=57) | 54.95 Units on a scale | Standard Deviation 31.23 |
| Tocilizumab | Change From Baseline in Patient Quality of Sleep VAS | Change at Week 2 (n=57) | -8.40 Units on a scale | Standard Deviation 23.72 |
| Tocilizumab | Change From Baseline in Patient Quality of Sleep VAS | Change at Week 24 (n=46) | -21.93 Units on a scale | Standard Deviation 30.87 |
| Tocilizumab | Change From Baseline in Patient Quality of Sleep VAS | Change at Week 52 (n=9) | -34.22 Units on a scale | Standard Deviation 37.03 |
Secondary
Change From Baseline in Patient's Assessment of Pain VAS
Patient's Assessment of Pain VAS represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS. The extreme left end of the line represents 0=no pain and the extreme right end 100=unbearable pain. A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 2 and Week 24
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tocilizumab | Change From Baseline in Patient's Assessment of Pain VAS | Baseline (n=57) | 66.77 Units on a scale | Standard Deviation 21.43 |
| Tocilizumab | Change From Baseline in Patient's Assessment of Pain VAS | Change at Week 2 (n=57) | -11.32 Units on a scale | Standard Deviation 19.74 |
| Tocilizumab | Change From Baseline in Patient's Assessment of Pain VAS | Change at Week 24 (n=46) | -35.37 Units on a scale | Standard Deviation 27.03 |
| Tocilizumab | Change From Baseline in Patient's Assessment of Pain VAS | Change at Week 52 (n=9) | -49.33 Units on a scale | Standard Deviation 39.58 |
Secondary
Change From Baseline in Patient Satisfaction VAS
The Patient Satisfaction VAS assessment represents the participant's assessment of his/her current satisfaction with treatment on a 100 mm horizontal VAS. The extreme left end of the line represents 0=no satisfaction and the extreme right end 100=extremely satisfied. A positive change from baseline indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tocilizumab | Change From Baseline in Patient Satisfaction VAS | Baseline (n=53) | 39.66 Units on a scale | Standard Deviation 28.63 |
| Tocilizumab | Change From Baseline in Patient Satisfaction VAS | Change at Week 2 (n=53) | 9.49 Units on a scale | Standard Deviation 33.97 |
| Tocilizumab | Change From Baseline in Patient Satisfaction VAS | Change at Week 24 (n=43) | 33.07 Units on a scale | Standard Deviation 35.5 |
| Tocilizumab | Change From Baseline in Patient Satisfaction VAS | Change at Week 52 (n=8) | 49.38 Units on a scale | Standard Deviation 35.12 |
Secondary
Change From Baseline in Patient's Global Assessment of Disease Activity VAS
PGA VAS represents the participant's overall assessment of their current disease activity on a 100 mm horizontal VAS. The extreme left end of the line represents 0= no disease activity (symptom-free and no arthritis symptoms) and the extreme right end 100=maximum disease activity (maximum arthritis disease activity). A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tocilizumab | Change From Baseline in Patient's Global Assessment of Disease Activity VAS | Baseline (n=57) | 67.28 Units on a scale | Standard Deviation 22.25 |
| Tocilizumab | Change From Baseline in Patient's Global Assessment of Disease Activity VAS | Change at Week 2 (n=57) | -11.82 Units on a scale | Standard Deviation 23.23 |
| Tocilizumab | Change From Baseline in Patient's Global Assessment of Disease Activity VAS | Change at Week 24 (n=46) | -36.02 Units on a scale | Standard Deviation 29.38 |
| Tocilizumab | Change From Baseline in Patient's Global Assessment of Disease Activity VAS | Change at Week 52 (n=9) | -44.78 Units on a scale | Standard Deviation 35.87 |
Secondary
Change From Baseline in Physician's Global Assessment of Disease Activity VAS
Physician's Global Assessment of disease activity VAS represents the physician's assessment of the participant's current disease activity on a 100 mm horizontal VAS. The extreme left end of the line represents 0= no disease activity (symptom-free and no arthritis symptoms) and the extreme right end 100= maximum disease activity. This was completed by the Treating Physician (or designee). A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tocilizumab | Change From Baseline in Physician's Global Assessment of Disease Activity VAS | Baseline (n=56) | 64.93 Units on a scale | Standard Deviation 17.73 |
| Tocilizumab | Change From Baseline in Physician's Global Assessment of Disease Activity VAS | Change at Week 2 (n=56) | -16.34 Units on a scale | Standard Deviation 16.88 |
| Tocilizumab | Change From Baseline in Physician's Global Assessment of Disease Activity VAS | Change at Week 24 (n=45) | -48.93 Units on a scale | Standard Deviation 25.06 |
| Tocilizumab | Change From Baseline in Physician's Global Assessment of Disease Activity VAS | Change at Week 52 (n=9) | -57.44 Units on a scale | Standard Deviation 23.26 |
Secondary
Change From Baseline in Pittsburgh Sleep Quality Index (PSQI)
The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over 1-month time interval. Nineteen individual items generate seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The participant self-rates each of these seven areas of sleep. Scoring of answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. Global scores range from 0 to 21 and a global sum of 5 or greater indicates a poor sleeper. Although there are several questions that request the evaluation of the participant's bed mate or roommate, these are not scored. A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 4, Week 24 and Week 52
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tocilizumab | Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) | Baseline (n=57) | 8.81 Units on a scale | Standard Deviation 4.39 |
| Tocilizumab | Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) | Change at Week 4 (n=54) | -1.24 Units on a scale | Standard Deviation 3.53 |
| Tocilizumab | Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) | Change at Week 24 (n=46) | -2.63 Units on a scale | Standard Deviation 4.14 |
| Tocilizumab | Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) | Change at Week 52 (n=9) | -4.56 Units on a scale | Standard Deviation 5.88 |
Secondary
Change From Baseline in Simplified Disease Activity Index (SDAI)/Clinical Disease Activity Index (CDAI)
SDAI is a similar index to DAS28 but has the advantage of not needing a complicated mathematical formula for its determination, but a simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS, and CRP concentration in mg/L. CDAI does not incorporate an acute response, therefore it can be used to evaluate disease activity in the absence of laboratory testing of CRP and ESR. VAS range for all assessments was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. SDAI scores ranged from 0 to 86, CDAI from 0 to 76 with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tocilizumab | Change From Baseline in Simplified Disease Activity Index (SDAI)/Clinical Disease Activity Index (CDAI) | Baseline (n=53) | 33.26 Units on a scale | Standard Deviation 13.5 |
| Tocilizumab | Change From Baseline in Simplified Disease Activity Index (SDAI)/Clinical Disease Activity Index (CDAI) | Change at Week 2: SDAI (n=52) | -9.00 Units on a scale | Standard Deviation 11.89 |
| Tocilizumab | Change From Baseline in Simplified Disease Activity Index (SDAI)/Clinical Disease Activity Index (CDAI) | Change at Week 24: SDAI (n=38) | -25.33 Units on a scale | Standard Deviation 13.63 |
| Tocilizumab | Change From Baseline in Simplified Disease Activity Index (SDAI)/Clinical Disease Activity Index (CDAI) | Change at Week 52: SDAI (n=7) | -34.04 Units on a scale | Standard Deviation 16.01 |
| Tocilizumab | Change From Baseline in Simplified Disease Activity Index (SDAI)/Clinical Disease Activity Index (CDAI) | Baseline: CDAI (n= 55) | 31.86 Units on a scale | Standard Deviation 12.6 |
| Tocilizumab | Change From Baseline in Simplified Disease Activity Index (SDAI)/Clinical Disease Activity Index (CDAI) | Change at Week 2: CDAI (n=55) | -7.61 Units on a scale | Standard Deviation 11.51 |
| Tocilizumab | Change From Baseline in Simplified Disease Activity Index (SDAI)/Clinical Disease Activity Index (CDAI) | Change at Week 24: CDAI (n=42) | -23.55 Units on a scale | Standard Deviation 13.03 |
| Tocilizumab | Change From Baseline in Simplified Disease Activity Index (SDAI)/Clinical Disease Activity Index (CDAI) | Change at Week 52: CDAI (n=8) | -29.99 Units on a scale | Standard Deviation 13.89 |
Secondary
Change From Baseline in Work Instability Scale for Rheumatoid Arthritis (RA-WIS)
The 23-item RA-WIS is a simple, validated screening tool for work instability, i.e., the consequences of a mismatch between an individual's functional ability and their work tasks. This self-administered questionnaire covers a broad range of specific work-related issues and enables monitoring the risk of work disability in rheumatoid arthritis patients. The RA-WIS is scored by summing responses from all 23 scale items. The scale ranges from 0 to 23. Cut points have been established to differentiate levels of work instability: low \< 10, moderate 10-17 and high \> 17. A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 24
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tocilizumab | Change From Baseline in Work Instability Scale for Rheumatoid Arthritis (RA-WIS) | Baseline (n=26) | 13.15 Units on a scale | Standard Deviation 6.05 |
| Tocilizumab | Change From Baseline in Work Instability Scale for Rheumatoid Arthritis (RA-WIS) | Change at Week 24 (n=22) | -3.55 Units on a scale | Standard Deviation 6.96 |
Secondary
Change in Total Tender/Swollen Joint Counts (TJC/SJC)
An assessment of 66 joints for swelling and 68 joints for tenderness was made. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints were not taken into consideration for swelling or tenderness. A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here, n is the number of participants with evaluable data for this outcome measure
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tocilizumab | Change in Total Tender/Swollen Joint Counts (TJC/SJC) | Baseline: TJC (n=53) | 16.02 Joint Counts | Standard Deviation 11.77 |
| Tocilizumab | Change in Total Tender/Swollen Joint Counts (TJC/SJC) | Change at Week 2: TJC (n=53) | -3.58 Joint Counts | Standard Deviation 8.91 |
| Tocilizumab | Change in Total Tender/Swollen Joint Counts (TJC/SJC) | Change at Week 24: TJC (n=41) | -12.10 Joint Counts | Standard Deviation 11.07 |
| Tocilizumab | Change in Total Tender/Swollen Joint Counts (TJC/SJC) | Change at Week 52: TJC (n=8) | -17.25 Joint Counts | Standard Deviation 13.02 |
| Tocilizumab | Change in Total Tender/Swollen Joint Counts (TJC/SJC) | Baseline: SJC (n=55) | 10.20 Joint Counts | Standard Deviation 7.14 |
| Tocilizumab | Change in Total Tender/Swollen Joint Counts (TJC/SJC) | Change at Week 2: SJC (n=55) | -3.93 Joint Counts | Standard Deviation 7.33 |
| Tocilizumab | Change in Total Tender/Swollen Joint Counts (TJC/SJC) | Change at Week 24: SJC (n=42) | -9.81 Joint Counts | Standard Deviation 7.84 |
| Tocilizumab | Change in Total Tender/Swollen Joint Counts (TJC/SJC) | Change at Week 52: SJC (n=8) | -11.75 Joint Counts | Standard Deviation 7.76 |
Secondary
Percentage of Participants Achieving a Clinically Significant Improvement in DAS28
The DAS28 score is a measure of the participant's disease activity calculated using TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. DAS28 Clinically Significant Improvement was defined as a DAS28 score reduction of at least 1.2 units from Baseline.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here, n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tocilizumab | Percentage of Participants Achieving a Clinically Significant Improvement in DAS28 | Week 2 (n=56) | 66.1 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving a Clinically Significant Improvement in DAS28 | Week 24 (n=42) | 90.5 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving a Clinically Significant Improvement in DAS28 | Week 52 (n=8) | 100 percentage of participants |
Secondary
Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity
CDAI is calculated by simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS. VAS range was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Total CDAI score ranges from 0 to 76 with higher scores indicating increased disease activity. Clinical remission = score ≤ 2.8; Low disease activity = score \> 2.8 and ≤ 10.0; Moderate disease activity = score \> 10.0 and ≤ 22.0; High disease activity = score \> 22.0.
Time frame: Baseline to Week 2, Week 24 and Week 52
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here, n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tocilizumab | Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity | Baseline: Clinical remission (n=55) | 0 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity | Week 2: Clinical remission (n=56) | 1.8 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity | Week 24: Clinical remission (n=43) | 30.2 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity | Week 52: Clinical remission (n=8) | 37.5 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity | Baseline: Low disease activity (n=55) | 0 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity | Week 2: Low disease activity (n=56) | 7.1 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity | Week 24: Low disease activity (n=43) | 34.9 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity | Week 52: Low disease activity (n=8) | 25.0 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity | Week 52: High disease activity (n=8) | 0 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity | Baseline: Moderate disease activity (n=55) | 21.8 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity | Week 2: Moderate disease activity (n=56) | 48.2 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity | Week 24: Moderate disease activity (n=43) | 30.2 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity | Week 52: Moderate disease activity (n=8) | 37.5 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity | Baseline: High disease activity (n=55) | 78.2 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity | Week 2: High disease activity (n=56) | 42.9 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity | Week 24: High disease activity (n=43) | 4.7 percentage of participants |
Secondary
Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity
The DAS28 score is a measure of the participant's disease activity calculated using TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. Clinical remission = score \<2.6; Low disease activity = score ≥2.6 and ≤3.2; Moderate disease activity = score \> 3.2 and ≤5.1; High disease activity = score \>5.1.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here, n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tocilizumab | Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity | Baseline: Clinical remission (n=56) | 0 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity | Week 2: Clinical remission (n=56) | 7.1 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity | Week 24: Clinical remission (n=42) | 64.3 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity | Week 52: Clinical remission (n=8) | 87.5 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity | Baseline: Low disease activity (n=56) | 1.8 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity | Week 2: Low disease activity (n=56) | 16.1 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity | Week 24: Low disease activity (n=42) | 16.7 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity | Week 52: Low disease activity (n=8) | 0 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity | Baseline: Moderate disease activity (n=56) | 35.7 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity | Week 2: Moderate disease activity (n=56) | 53.6 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity | Week 24: Moderate disease activity (n=42) | 19.0 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity | Week 52: Moderate disease activity (n=8) | 12.5 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity | Baseline: High disease activity (n=56) | 62.5 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity | Week 2: High disease activity (n=56) | 23.2 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity | Week 24: High disease activity (n=42) | 0 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity | Week 52: High disease activity (n=8) | 0 percentage of participants |
Secondary
Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity
SDAI is calculated by simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS, and CRP concentration in mg/L. VAS range was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Total SDAI score ranges from 0 to 86 with higher scores indicating increased disease activity. Clinical remission = score ≤ 3.3; Low disease activity = score \> 3.3 and ≤ 11.0; Moderate disease activity = score \> 11.0 and ≤ 26.0; high disease activity = score \> 26.0.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here, n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tocilizumab | Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity | Week 52: High disease activity (n=7) | 0 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity | Baseline: Clinical remission (n=53) | 0 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity | Week 2: Clinical remission (n=55) | 1.8 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity | Week 24: Clinical remission (n=40) | 30.0 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity | Week 52: Clinical remission (n=7) | 42.9 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity | Baseline: Low disease activity (n=53) | 0 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity | Week 2: Low disease activity (n=55) | 7.3 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity | Week 24: Low disease activity (n=40) | 40.0 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity | Week 52: Low disease activity (n=7) | 14.3 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity | Baseline: Moderate disease activity (n=53) | 30.2 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity | Week 2: Moderate disease activity (n=55) | 54.5 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity | Week 24: Moderate disease activity (n=40) | 25.0 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity | Week 52: Moderate disease activity (n=7) | 42.9 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity | Baseline: High disease activity (n=53) | 69.8 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity | Week 2: High disease activity (n=55) | 36.4 percentage of participants |
| Tocilizumab | Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity | Week 24: High disease activity (n=40) | 5.0 percentage of participants |
Secondary
Percentage of Participants With Corticosteroid Dose Reduction/Discontinuation
Time frame: Up to Week 52
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here, number of participants analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Tocilizumab | Percentage of Participants With Corticosteroid Dose Reduction/Discontinuation | 50.0 percentage of participants |
Secondary
Percentage of Participants With Positive American College of Rheumatology (ACR) Response Scores
The ACR core set of outcome measures and their definition of improvement includes a \>= 20% improvement (ACR20) compared to Baseline in both SJC and TJC as well as in three out of five additional parameters: Physician's Global Assessment of disease activity VAS, PGA VAS, patient's assessment of pain VAS, Health Assessment Questionnaire-Disability Index (HAQ-DI), and acute phase reactant (CRP or ESR). VAS range for all assessments was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Achievement of an ACR50 requires a \>= 50% improvement in the same parameters and an ACR70 requires a \>= 70% improvement.
Time frame: From Baseline to Week 2, Week 24, and Week 52
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here, n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tocilizumab | Percentage of Participants With Positive American College of Rheumatology (ACR) Response Scores | Baseline: ACR 20 (n=55) | 0 percentage of participants |
| Tocilizumab | Percentage of Participants With Positive American College of Rheumatology (ACR) Response Scores | Week 2: ACR 20 (n=51) | 21.6 percentage of participants |
| Tocilizumab | Percentage of Participants With Positive American College of Rheumatology (ACR) Response Scores | Week 24: ACR 20 (n=39) | 84.6 percentage of participants |
| Tocilizumab | Percentage of Participants With Positive American College of Rheumatology (ACR) Response Scores | Week 52: ACR 20 (n=8) | 100 percentage of participants |
| Tocilizumab | Percentage of Participants With Positive American College of Rheumatology (ACR) Response Scores | Baseline: ACR 50 (n=55) | 0 percentage of participants |
| Tocilizumab | Percentage of Participants With Positive American College of Rheumatology (ACR) Response Scores | Week 2: ACR 50 (n=52) | 1.9 percentage of participants |
| Tocilizumab | Percentage of Participants With Positive American College of Rheumatology (ACR) Response Scores | Week 24: ACR 50 (n=39) | 66.7 percentage of participants |
| Tocilizumab | Percentage of Participants With Positive American College of Rheumatology (ACR) Response Scores | Week 52: ACR 50 (n=8) | 62.5 percentage of participants |
| Tocilizumab | Percentage of Participants With Positive American College of Rheumatology (ACR) Response Scores | Baseline: ACR 70 (n=55) | 0 percentage of participants |
| Tocilizumab | Percentage of Participants With Positive American College of Rheumatology (ACR) Response Scores | Week 2: ACR 70 (n=52) | 0 percentage of participants |
| Tocilizumab | Percentage of Participants With Positive American College of Rheumatology (ACR) Response Scores | Week 24: ACR 70 (n=39) | 38.5 percentage of participants |
| Tocilizumab | Percentage of Participants With Positive American College of Rheumatology (ACR) Response Scores | Week 52: ACR 70 (n=8) | 25.0 percentage of participants |
Secondary
Percentage of Participants With Responses According to European League Against Rheumatism (EULAR ) Criteria
EULAR response was calculated as the difference between DAS28-ESR scores at baseline and Week 24, and reported as the percentage of participants with good, moderate, or no response. Good responders = decrease from baseline \>1.2 with a DAS28 score of \<=3.2; moderate responders = decrease from baseline \>1.2 with a DAS28 score of \>3.2, or decrease from baseline \>0.6 to \<=1.2 with a DAS28 score of \<=5.1; non-responders = decrease from baseline \<=0.6 or decrease from baseline \>0.6 and \<=1.2 with a DAS28 score of \>5.1.
Time frame: From Baseline to Week 2, Week 24
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tocilizumab | Percentage of Participants With Responses According to European League Against Rheumatism (EULAR ) Criteria | Week 2: No response (n=56) | 32.1 percentage of participants |
| Tocilizumab | Percentage of Participants With Responses According to European League Against Rheumatism (EULAR ) Criteria | Week 2: Good response (n=56) | 17.9 percentage of participants |
| Tocilizumab | Percentage of Participants With Responses According to European League Against Rheumatism (EULAR ) Criteria | Week 24: Good response (n=42) | 76.2 percentage of participants |
| Tocilizumab | Percentage of Participants With Responses According to European League Against Rheumatism (EULAR ) Criteria | Week 2: Moderate response (n=56) | 50.0 percentage of participants |
| Tocilizumab | Percentage of Participants With Responses According to European League Against Rheumatism (EULAR ) Criteria | Week 24: Moderate response (n=42) | 19.0 percentage of participants |
| Tocilizumab | Percentage of Participants With Responses According to European League Against Rheumatism (EULAR ) Criteria | Week 24: No response (n=42) | 4.8 percentage of participants |
Secondary
Safety: Percentage of Participants With Adverse Events
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time frame: Up to 52 weeks
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Tocilizumab | Safety: Percentage of Participants With Adverse Events | 96.5 percentage of participants |
Secondary
Safety: Percentage of Participants With Anti-tocilizumab Antibodies
Time frame: Baseline, Week 24
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here, n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tocilizumab | Safety: Percentage of Participants With Anti-tocilizumab Antibodies | Baseline (n= 55) | 0 percentage of participants |
| Tocilizumab | Safety: Percentage of Participants With Anti-tocilizumab Antibodies | Week 24 (n= 43) | 1.7 percentage of participants |
Secondary
Treatment Satisfaction Questionnaire for Medication (TSQM ) Scores
The abbreviated 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) derived from the TSQM Version 1.4 but without the five items of the side effects domain, is a reliable and valid measure to assess participants' satisfaction with treatment. The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain. Domains included are effectiveness, convenience and global satisfaction.
Time frame: Week 24
Population: The FAS consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab. Here n is the number of participants with evaluable data for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Tocilizumab | Treatment Satisfaction Questionnaire for Medication (TSQM ) Scores | Effectiveness (n=46) | 66.7 Units on a scale | Standard Deviation 19.07 |
| Tocilizumab | Treatment Satisfaction Questionnaire for Medication (TSQM ) Scores | Convenience (n=46) | 76.09 Units on a scale | Standard Deviation 15.66 |
| Tocilizumab | Treatment Satisfaction Questionnaire for Medication (TSQM ) Scores | Global Satisfaction (n=46) | 65.06 Units on a scale | Standard Deviation 15.52 |